Vaxcyte announces positive Phase 3 OPUS-1 topline data for VAX-31 pneumococcal vaccine

Vaxcyte reported positive topline safety, tolerability and immunogenicity results from the Phase 3 OPUS-1 pivotal trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. A successful pivotal trial readout for a late-stage vaccine program materially de-risks the development path and increases the probability of regulatory approval and market entry.

Vaxcyte announced its experimental pneumococcal vaccine candidate passed its big clinical trial with positive results. This is a key milestone that makes it more likely the vaccine will eventually be approved and sold.